Fig. 2. Risk stratification according to liquid biopsy results and clinicopathological features among patients treated with first-line ICIs and high PD-L1 expression.

A Kaplan–Meier curve for PFS (A) of patients treated with first-line pembrolizumab and stratified into three risk groups based on their individual scores in the nomogram. Factors affecting PFS in multiple regression models were: maxVAF at T2 and increase (∆T2–T1) of cfDNA. B Kaplan–Meier curves for the OS of patients treated with first-line pembrolizumab and stratified into three risk groups based on their individual scores in the nomogram. Factors affecting OS in multiple regression models were: maxVAF at T2 and increase (∆T2–T1) of cfDNA.